Blog posts of '2021' 'September'

Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir use with Sofosbuvir with or without Ribavirin to treat HCV genotype 1 and 3 infections. Daclatasvir was FDA-approved in July 2015.

Dabigatran is a direct inhibitor of thrombin and anticoagulant which is used for prevention of stroke and venous embolism in patients with chronic atrial fibrillation. Dabigatran was approved for medical use in 2010.